NEW YORK (GenomeWeb News) – Swift Biosciences announced today a licensing deal with Vela Operations for the rights to Swift's myT Primer Technology.

The terms of the agreement give Vela Diagnostics the non-exclusive rights to use Swift's technology in Vela's real-time quantitative PCR-based IVD products for detecting somatic mutations in human cancer. Vela will seek regulatory approval for the assay kits globally and Swift will develop myT Primers for research-use only applications.

Further terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.